Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomised controlled trial

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Ketorolac is at least as effective as morphine, with improved patient satisfaction and a lower incidence of adverse events. Furthermore it represents a cost-effective alternative to morphine for pain management within an accident and emergency department, as costs of administration and treatment of adverse events are lower than they are for morphine. The authors note that their economic conclusions may not be generalisable outside systems similar to those in Hong Kong.